December 30, 2008
Back in June, the maker of Botox was seeking FDA approval of its eyelash-boosting drug. Now, Allergan got its wish: the FDA has approved Latisse, an eyelash-thickening agent meant for people who have hypotrichosis of the eyelashes in other words, too few lashes.
Latisse's active ingredient is bimatroprost, which happens to be the same ingredient used in glaucoma treatments. Side effects may include itchy eyes, eye redness, a change in skin color, and a potentially permanent darkening of the iris. (Ha--makes you want to run out and buy it, doesn't it?)
33 queries taking 1.5523 seconds, 127 records returned.
Powered by Minx 1.1.6c-pink.